Drug Evaluations, 6th ed., (1986), American Medical Assn., pp. 1081, 1171-1179, 1200-1201, 1204, 1207, 1218. |
The Merck Index, 11th ed., (1989), Merck & Co., Inc., p. 445. |
Thimmaiah et al., CA115:197724m (1990). |
Suzuki et al, CA 83:193345m (1975). |
Gal et al, CA 60:1738e-g (1963). |
Samolovova et al, CA 55:23540i (1961). |
Sen et al, CA 56:8711b (1961). |
Antoni, CA 60:8023a (1963). |
Caldwell, CA 53:17155c (1959). |
Frangatos et al, CA 54:21103c (1960). |
Shirley et al., CA 57:8567d (1961). |
Vanderhaeghe et al, CA 56:10137g (1961). |
Yarmukhametova et al, CA 84:4884y (1975) and CA 92:64849 (1979). |
Ford et al., "Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug Resistance", Molecular Pharmacology, 35:105-115 (1988). |
Aklyama et al., "Circumvention of Multiple-Drug Resistance in Human Cancer Cells by Thioridazine, Trifluoperazine, and Chlorpromazine", JNCL, vol. 76, No. 5, May 1986, pp. 839-844. |
Tsuruo et al., "Increased Accumulation of Vincristine and Adriamycin in Drug-risistance P388 Tumor Cells Following Incubation with Calcium Antagonists and Calmodulin Inhibitors", Cancer Research, 42, pp. 4730-4733, Nov. 1982. |
Zamora et al., "Physical-Chemical Properties Shared by Compunds that Modulate Multidrug Resistance in Human Leukemic Cells", Molecular Pharmacology, 33:454-462 (1988). |
Kessel et al., "Promotion of Daunorubicin Uptake and Toxicity by the Calcium Antagonist Tiapamil and Its Analogs", Cancer Treatment Reports, vol. 69, No. 6, Jun. 1985, pp. 673-676. |
Shiraishi et al., "Lysosomotropic Agents Reverse Multiple Drug Resistance in Human Cancer Cells", Cancer Letters, 30 (1986) pp. 251-259. |
Yamaguchi et al., "Overcoming Drug Resistance in Cancer Cells with Synthetic Isoprenoids", JNCL, vol. 76, No. 5, May 1986, pp. 947-953. |
Sloviter, "Halogenated Benzophenoxazine Dyes", [Contribution from the Harrison Department of Surgical Research, School of Medicine, University of Pennsylvania, and the Department of Neurosurgery, Hospital of the University of Pennsylvania], vol. 71, pp. 3360-3362, J. Amer. Chem. Soc. (1949). |
Crossley et al., "Chemotherapeutic Dyes. I. 5-Aralkylamino-9-alkylaminobenzo[a]phenoxazines", Journal of the American Chemical Society, vol. 74, Feb. 5, 1952, No. 3, pp. 573-586. |
Sen et al., "Potential Carcinostatic Derivatives of Benzo[a]- and Benzo[b]phenoxazine", [Contribution from the Department of Chemistry, the University of Tennessee], Oct. 1961, pp. 3861-3863, J. Org. Chem. |
Sen et al., "Syntheses of 5-[4-{N,N-Bis(2-chloroethyl)amino}benzylamino]-9-N,N-dialkyl-aminobenzo[a]phenoxazonium Chlorides", Indian Journal of Chemistry, vol. 21B, Jul. 1982, pp. 642-645. |
Cincotta et al., "Novel Red Absorbing Benzo[a]phenoxazinium and Benzo[s]phenothiazinium Photosensitizers: In Vitro Evaluation", Photochemistry and Photobiology, vol. 46, No. 5, pp. 751-758, 1987. |
Jain et al., "Potential Anticancer Agents: Synthesis of Amides & Esters of 2-Amino-4,6-dimethyl-3-oxophenoxazine-I,9-dicarboxylic Acid", Indian Journal of Chemistry, vol. 15B, Feb. 1977, pp. 163-164. |
Palmer et al., "Potential Antitumor Agents. 54. Chromophore Requirements for In Vivo Antitumor Activity Among the General Class of Linear Tricyclic Carboxamides", J. Med. Chem., 1988, 31, pp. 707-712. |
Sengupta et al., "`Reverse` and `Symmetrical` Analogues of Actinomycin D: Metabolic Activation and In Vitro and In Vivo Tumor Growth Inhibitory Activities", J. Med. Chem., 1985, vol. 28, No. 5, pp. 620-628. |
Kanzawa, et al., "Antitumor Activity of Haloacetylcarbazole Derivatives", Gann, The Japanese Journal of Cancer Research, 64, pp. 391-396 (1973). |